Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy

This article was originally published in The Tan Sheet

Executive Summary

First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.

Advertisement

Related Content

Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims
Selenium Claim Ruling Forces FDA's Hand, May Clear Path For More QHCs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register